dinap
e
analog
natur
product
chalcon
flavokawain
synthes
character
studi
porcin
reproduct
respiratori
syndrom
viru
prrsv
challeng
threat
swine
industri
worldwid
current
commerci
avail
vaccin
ineffect
control
porcin
reproduct
respiratori
syndrom
prr
pig
therefor
pharmacolog
intervent
may
repres
altern
control
measur
prrsv
infect
henc
present
studi
evalu
effect
dinap
replic
prototyp
strain
type
prrsv
initi
vitro
antivir
assay
perform
cell
porcin
alveolar
macrophag
pam
follow
pilot
studi
conduct
pig
model
demonstr
effect
dinap
follow
infect
dinap
inhibit
replic
cell
line
dosedepend
manner
viral
growth
complet
suppress
concentr
mm
without
signific
cytotox
consist
find
pig
studi
dinap
also
reduc
viral
load
serum
lung
enhanc
weight
gain
pig
follow
infect
indic
comparison
dinaptr
group
untreat
control
nc
group
addit
dinaptr
pig
fewer
gross
microscop
lesion
lung
nc
pig
notabl
viru
transmiss
also
delay
approxim
week
uninfect
contact
pig
within
group
treatment
dinap
taken
togeth
result
suggest
dinap
potenti
antiprrsv
activ
could
use
prophylact
postexposur
treatment
drug
control
prrsv
infect
pig
porcin
reproduct
respiratori
syndrom
prr
econom
import
infecti
diseas
swine
industri
worldwid
prr
character
reproduct
failur
sow
respiratori
diseas
pig
age
annual
loss
associ
prr
approxim
million
usd
estim
swine
produc
unit
state
prr
viru
prrsv
member
arterivirida
viru
famili
order
nidoviral
along
equin
arter
viru
eav
murin
lactat
dehydrogenaseelev
viru
ldv
simian
hemorrhag
fever
viru
shfv
prrsv
small
envelop
viru
singlestrand
nonseg
positivesens
rna
genom
approxim
kb
length
genom
prrsv
encod
least
ten
open
read
frame
orf
call
prrsv
use
group
european
type
north
american
type
genotyp
current
classifi
two
speci
betaarteriviru
suid
betaarteriviru
suid
respect
substanti
genet
antigen
variat
among
prrsv
strain
even
within
viru
speci
sinc
first
emerg
prr
two
decad
ago
numer
effort
made
develop
effect
control
measur
challeng
diseas
current
vaccin
primari
control
method
wide
use
control
prr
pig
howev
use
commerci
vaccin
either
modifi
live
viru
mlv
kill
viru
inadequ
control
prrsv
infect
highli
diverg
prrsv
strain
field
antivir
therapeut
could
altern
addit
control
measur
combat
viral
infect
success
vaccin
match
circul
viru
avail
therefor
pharmacolog
intervent
might
suitabl
use
control
strategi
prr
mani
previou
studi
report
varieti
natur
compound
proven
exert
antivir
activ
number
virus
equin
herpesviru
hepat
b
viru
human
cytomegaloviru
hcmv
respiratori
infect
includ
common
cold
prrsv
howev
effect
drug
commerci
avail
prevent
prrsv
infect
chalcon
constitut
key
class
natur
product
belong
flavonoid
famili
previous
report
wide
rang
biolog
activ
antivir
antibacteri
antifung
immunomodulatori
antiinflammatori
antitumor
insect
antifeed
antimutagen
activ
thu
present
studi
aim
evalu
antivir
effect
dinap
e
synthet
analog
chalcon
flavokawain
prrsv
replic
cell
cultur
system
studi
carri
pig
model
demonstr
inhibitori
effect
dinap
prrsv
infect
synthesi
flavokawain
analog
dinap
present
scheme
began
prepar
compound
quantit
obtain
reaction
dimethyl
sulfat
presenc
potassium
carbon
aceton
correspond
acetophenon
subject
claisenschmidt
condens
reaction
presenc
potassium
hydroxid
methanol
provid
flavokawain
analog
dinap
yield
scheme
synthesi
e
dinap
antivir
effect
dinap
prrsv
replic
evalu
cell
porcin
alveolar
macrophag
pam
dinap
reduc
replic
cell
line
dosedepend
manner
figur
cell
replic
decreas
approxim
presenc
dinap
concentr
mm
respect
viral
growth
complet
suppress
mm
concentr
dinap
lowest
concentr
mm
exert
signific
effect
viral
replic
figur
addit
dinap
show
signific
toxic
cell
even
concentr
mm
h
post
treatment
hpt
figur
consist
result
obtain
cell
pam
dinap
also
reduc
replic
approxim
presenc
mm
concentr
highest
concentr
mm
caus
complet
suppress
replic
mm
dinap
effect
figur
similarli
dinap
caus
signific
toxic
pam
even
concentr
mm
hpt
figur
prototyp
prrsv
evalu
five
differ
concentr
mm
cell
porcin
alveolar
macrophag
pam
b
measur
progeni
viru
product
time
type
cell
prepar
cell
cultur
plate
cell
monolay
pretreat
h
infect
growth
medium
contain
dinap
cell
inocul
moi
incub
addit
hour
cell
monolay
replenish
growth
medium
contain
concentr
dinap
incub
addit
day
cultur
condit
mtt
bromid
assay
also
conduct
cell
line
assess
cytotox
dinap
cell
c
pam
concentr
describ
cytotox
data
express
rel
cell
viabil
asterisk
indic
signific
differ
p
p
viral
replic
group
viral
load
serum
sampl
quantifi
realtim
revers
transcriptionpolymeras
chain
reaction
qrtpcr
taqman
result
summar
figur
one
pig
group
challeng
maintain
group
two
unchalleng
pig
observ
effect
dinap
viru
transmiss
challeng
unchalleng
pig
group
nc
pig
challeng
highest
viral
load
viru
titer
tcid
ml
day
post
challeng
dpc
gradual
decreas
tcid
ml
dpc
similarli
two
unchalleng
pig
group
also
show
peak
viral
titer
tcid
ml
dpc
also
gradual
decreas
tcid
ml
respect
dpc
figur
group
dinap
mmkg
bodi
weight
pig
challeng
peak
viral
titer
tcid
ml
dpc
lower
titer
found
pig
challeng
viru
group
viral
titer
gradual
decreas
tcid
ml
dpc
among
two
unchalleng
pig
group
one
pig
show
peak
viru
titer
tcid
ml
dpc
also
lower
titer
unchalleng
pig
group
titer
gradual
declin
tcid
ml
dpc
unchalleng
pig
show
viremia
dpc
although
viru
detect
dpc
titer
tcid
ml
slowli
decreas
tcid
ml
dpc
figur
consist
result
group
dinap
mmkg
bodi
weight
pig
challeng
peak
viremia
viru
titer
tcid
ml
dpc
lower
titer
found
pig
challeng
viru
group
viru
titer
gradual
decreas
tcid
ml
dpc
neither
unchalleng
pig
group
display
viremia
dpc
although
viru
detect
pig
dpc
titer
tcid
ml
slowli
declin
tcid
ml
respect
dpc
figur
addit
averag
viru
titer
measur
pig
group
pig
group
nc
exhibit
averag
peak
viremia
titer
tcid
ml
dpc
gradual
decreas
tcid
ml
dpc
contrast
pig
group
dinap
mm
dinap
mm
averag
titer
tcid
ml
tcid
ml
respect
dpc
approxim
p
p
lower
averag
titer
observ
pig
group
nc
figur
result
suggest
dinap
signific
antivir
effect
prrsv
decreas
viral
transmiss
replic
pig
serum
viremia
measur
pig
serum
group
challeng
dpc
realtim
revers
transcriptionpolymeras
chain
reaction
qrtpcr
taqman
viral
rna
extract
serum
sampl
viral
load
quantifi
qrtpcr
level
viremia
calcul
express
tcid
ml
equival
base
standard
curv
cycl
threshold
ct
number
plot
known
viru
titer
measur
viru
titer
serum
sampl
present
individu
anim
averag
group
b
asterisk
indic
signific
differ
p
viru
titer
group
note
v
indic
pig
challeng
viru
group
prrsvspecif
antibodi
igg
respons
measur
serum
sampl
enzymelink
immunosorb
assay
elisa
base
nucleocapsid
n
protein
summar
figur
pig
group
seroneg
dpc
follow
infect
pig
group
nc
becam
seroposit
dpc
sp
sampletoposit
ratio
gradual
increas
dpc
similarli
group
two
pig
viru
challeng
unchalleng
becam
seroposit
dpc
unchalleng
pig
group
seroneg
dpc
becam
seroposit
dpc
group
challeng
pig
becam
seroposit
dpc
similar
challeng
pig
group
howev
two
unchalleng
pig
group
seroneg
dpc
becam
seroposit
dpc
differ
antibodi
igg
titer
found
among
group
figur
result
suggest
dinap
delay
viral
transmiss
among
pig
infect
prrsv
figur
antiprrsv
antibodi
igg
respons
measur
enzymelink
immunosorb
assay
elisa
pig
group
prrsvspecif
antibodi
igg
detect
serum
sampl
use
commerci
avail
elisa
kit
idexx
prr
ab
test
sp
ratio
ratio
net
optic
densiti
test
sampl
net
optic
densiti
posit
control
consid
posit
prrsv
antibodi
result
express
sp
ratio
sampl
sp
consid
posit
prrsv
antibodi
igg
note
v
indic
pig
challeng
viru
group
effect
dinap
growth
rate
pig
evalu
cours
prrsv
infect
averag
daili
weight
gain
adwg
measur
pig
group
dpc
dinap
significantli
enhanc
adwg
treatment
group
group
compar
pig
group
nc
figur
adwg
calcul
pig
group
day
express
kgday
asterisk
indic
signific
differ
p
adwg
pig
group
pig
untreat
control
group
group
exhibit
higher
lung
lesion
score
gross
microscop
group
group
figur
residu
viral
load
also
measur
lung
tissu
collect
pig
group
dinap
appear
reduc
viral
load
observ
lung
tissu
pig
treatment
group
group
compar
group
nc
pig
group
exhibit
averag
viru
titer
tcid
ml
tcid
ml
respect
approxim
lower
titer
tcid
ml
observ
group
group
pig
challeng
viru
titer
tcid
ml
lung
tissu
unchalleng
pig
group
exhibit
viru
titer
tcid
ml
respect
howev
group
pig
challeng
viru
viru
titer
tcid
ml
approxim
lower
titer
found
challeng
pig
group
two
unchalleng
pig
group
titer
tcid
ml
respect
also
lower
similar
titer
found
unchalleng
pig
group
group
pig
challeng
viru
exhibit
viru
titer
tcid
ml
lung
tissu
also
lower
titer
found
pig
challeng
viru
group
moreov
unchalleng
pig
group
also
lower
viru
titer
tcid
ml
respect
lung
tissu
titer
found
unchalleng
pig
group
figur
figur
quantif
residu
viral
load
lung
tissu
collect
pig
group
dpc
viral
rna
extract
lung
viral
load
lung
tissu
quantifi
qrtpcr
viral
load
lung
tissu
measur
express
tcid
ml
equival
base
standard
curv
ct
number
plot
known
viru
titer
asterisk
indic
signific
differ
p
viru
titer
group
chalcon
flavokawain
found
exhibit
promis
anticanc
antiinflammatori
properti
previou
studi
dinap
synthet
analog
chalcon
flavokawain
evalu
studi
potenti
antivir
activ
prrsv
infect
cell
cultur
system
pig
model
chemic
dinap
synthet
analog
flavokawain
contain
chalcon
scaffold
dinap
moieti
posit
common
structur
featur
natur
occur
compound
flavokawain
b
c
dinap
also
contain
naphthalenyl
moieti
posit
found
sever
antivir
agent
addit
chalcon
main
pharmacophor
dinap
report
show
wide
spectrum
biolog
activ
includ
antivir
antioxid
antiinflammatori
activ
previou
studi
support
result
present
current
studi
dinap
effect
suppress
replic
cell
pam
concentr
rang
mm
without
show
signific
cytotox
even
hpt
worth
note
highest
concentr
dinap
mm
use
studi
complet
suppress
replic
cell
line
figur
although
approxim
cell
death
observ
dinap
ad
mm
signific
side
effect
toxic
observ
treatment
pig
pig
experi
demonstr
dinap
exert
potenti
inhibitori
effect
prrsv
infect
dosedepend
manner
compar
pig
untreat
control
group
group
pig
treat
dinap
group
group
reduc
viral
load
serum
lung
increas
weight
gain
figur
consist
find
pig
treat
dinap
also
fewer
lesion
gross
microscop
lung
control
pig
figur
suggest
dinap
exert
signific
effect
prrsv
infect
importantli
two
inject
dinap
abl
delay
viru
transmiss
approxim
week
direct
contact
infect
viru
challeng
uninfect
viru
challeng
pig
treatment
group
group
howev
viru
easili
transmit
infect
uninfect
pig
untreat
control
group
group
indic
dinap
could
use
prophylact
postexposur
treatment
agent
case
prrsv
infect
dinap
produc
limit
quantiti
laboratori
scale
antivir
effect
dinap
preliminarili
evalu
small
number
pig
current
studi
therefor
detail
anim
experi
need
determin
long
antivir
effect
dinap
last
futur
taken
togeth
result
demonstr
dinap
might
use
potenti
prophylact
postexposur
antiprrsv
drug
treatment
prrsvinfect
pig
although
efficaci
safeti
longterm
use
higher
concentr
dinap
remain
confirm
futur
experi
reagent
solvent
purchas
sigmaaldrich
milwauke
wi
usa
alfa
aesar
ward
hill
usa
experi
involv
moisturesensit
compound
carri
argon
atmospher
analyt
thinlay
chromatographi
perform
precoat
silica
gel
f
thin
layer
chromatographi
tlc
plate
e
merck
kenilworth
nj
usa
visual
uv
light
final
product
purifi
prepar
mediumpressur
liquid
chromatographi
mplc
biotag
isolera
one
instrument
silica
column
biotag
snap
hpsil
spectromet
biotag
uppsala
sweden
nuclear
magnet
reson
nmr
analys
perform
use
bruker
mhz
h
mhz
c
spectromet
bruker
rheinstetten
germani
chemic
shift
report
part
per
million
deuterium
lock
signal
sampl
solvent
use
refer
coupl
constant
j
given
hertz
hz
split
pattern
abbrevi
follow
singlet
doublet
triplet
q
quartet
dd
doublet
doublet
multiplet
puriti
test
compound
confirm
higher
analyt
highperform
liquid
chromatographi
hplc
analysi
perform
dualpump
shimadzu
system
equip
vpod
column
mm
mm
shimadzu
mixtur
trihydroacetophenon
hydrat
g
mmol
potassium
carbon
g
mmol
dimethylsulf
ml
mmol
aceton
ml
stir
argon
c
h
result
mixtur
cool
room
temperatur
filter
wash
aceton
filtrat
extract
ethyl
acet
organ
layer
wash
three
time
satur
nahco
solut
dri
na
concentr
reduc
pressur
produc
compound
yield
r
f
ethyl
acet
hexan
dinap
synthes
follow
procedur
report
literatur
slight
modif
briefli
mixtur
compound
g
mmol
ml
mmol
potassium
hydroxid
g
methanol
ml
stir
c
day
mixtur
extract
ethyl
acet
organ
layer
wash
three
time
water
dri
na
concentr
reduc
pressur
purifi
mplc
produc
dinap
yield
r
f
ethyl
acet
hexan
prototyp
strain
type
prrsv
use
present
studi
african
green
monkey
kidney
cell
line
highli
permiss
prrsv
pam
primari
target
cell
prrsv
replic
pig
use
vitro
experi
pam
collect
prrsvfree
pig
bronchoalveolar
lavag
describ
previous
cell
use
viru
propag
antivir
assay
perform
cell
line
pam
cell
line
maintain
medium
gibco
invitrogen
carlsbad
ca
usa
supplement
heatinactiv
fetal
bovin
serum
fb
gibco
invitrogen
mm
lglutamin
antibioticantimycot
solut
antianti
invitrogen
solut
contain
iuml
penicillin
streptomycin
fungizon
amphotericin
b
name
growth
medium
c
humidifi
co
atmospher
cell
pam
prepar
cell
cultur
plate
bd
falcon
h
start
experi
follow
cell
monolay
pretreat
h
infect
growth
medium
contain
dinap
five
differ
concentr
mm
pretreat
incub
cell
monolay
wash
growth
medium
inocul
multipl
infect
moi
incub
h
final
incub
viral
inoculum
discard
cell
monolay
replenish
growth
medium
contain
concentr
dinap
treatment
incub
day
cultur
condit
cell
cultur
supernat
collect
everi
h
centrifug
store
c
analysi
progeni
viru
titer
measur
use
microtitr
infect
assay
viru
titrat
assay
describ
briefli
previou
studi
viru
titer
calcul
base
cytopath
effect
cpe
express
tcid
ml
cytotox
effect
dinap
assess
cell
pam
use
mtt
bromid
mtt
sigmaaldrich
st
loui
mo
usa
assay
describ
previous
brief
cell
pam
prepar
cell
cultur
plate
bd
falcon
treat
growth
medium
contain
dinap
mm
h
incub
cell
supernat
discard
freshli
made
mtt
mgml
solut
ad
along
growth
medium
well
cell
incub
anoth
h
condit
incub
mtt
solut
remov
plate
dri
c
overnight
dimethyl
sulfoxid
dmso
hybrimax
sigmaaldrich
ad
well
dissolv
formazan
crystal
plate
incub
c
min
dissolv
air
bubbl
mtt
signal
measur
use
elisa
micropl
reader
absorb
nm
total
threeweekold
prrsvneg
pig
purchas
arriv
facil
pig
randomli
hous
three
group
pig
per
group
design
group
pig
group
pig
group
pig
allow
acclimat
day
qrtpcr
taqman
elisa
use
confirm
pig
neg
prrsv
day
one
pig
group
respect
group
challeng
titer
ml
tcid
mlpig
intranas
rout
challeng
pig
maintain
group
observ
transmiss
viru
unchalleng
contact
pig
day
pig
group
group
inject
mm
mmkg
bodi
weight
mm
mmkg
bodi
weight
dinap
prepar
ml
dmso
behind
base
ear
intramuscularli
im
respect
pig
group
constitut
nontreat
challeng
control
nc
group
treatment
dinap
repeat
concentr
dpc
pig
observ
daili
clinic
sign
dpc
pig
weigh
challeng
dpc
serum
sampl
collect
challeng
dpc
virolog
serolog
assay
end
dpc
pig
euthan
result
patholog
examin
includ
presenc
gross
lung
lesion
record
expert
pathologist
base
standard
score
system
describ
previous
addit
lung
tissu
sampl
collect
neutral
buffer
formalin
examin
microscop
chang
furthermor
addit
lung
tissu
sampl
collect
store
c
analysi
viral
load
quantifi
serum
lung
tissu
sampl
anim
experi
protocol
approv
chonbuk
nation
univers
institut
anim
care
use
committe
approv
number
prrsvspecif
antibodi
igg
detect
serum
sampl
group
use
commerci
avail
elisa
kit
idexx
prr
ab
test
idexx
laboratori
ag
bern
switzerland
follow
instruct
suppli
manufactur
sp
ratio
ratio
net
optic
densiti
test
sampl
net
optic
densiti
posit
control
consid
posit
prrsv
antibodi
end
dpc
lung
euthan
pig
score
gross
lesion
immedi
necropsi
microscop
lesion
also
score
lung
tissu
section
stain
hematoxylin
eosin
h
e
score
microscop
lesion
perform
accord
scale
depend
degre
inflamm
especi
presenc
interstiti
pneumonia
indic
lesion
indic
mild
interstiti
pneumonia
indic
moderatemultifoc
interstiti
pneumonia
indic
sever
intensediffus
interstiti
pneumonia
viral
rna
extract
serum
lung
tissu
sampl
use
viral
rna
isol
kit
ambion
appli
biosystem
life
technolog
inc
carlsbad
ca
usa
total
rna
extract
kit
hybridrtm
geneal
seoul
korea
respect
accord
manufactur
instruct
viral
load
serum
tissu
quantifi
realtim
revers
transcriptionpolymeras
chain
reaction
qrtpcr
use
taqman
assay
base
previou
studi
primer
probe
sequenc
follow
forward
primer
tgtcagattcagggagrataagttac
probe
tgtggagttyagtytgcc
revers
primer
atcargcgcacagtrtgatgc
onestep
quantit
realtim
rtpcr
qrtpcr
kit
onestep
rtpcr
ambion
appli
biosystem
life
technolog
inc
carlsbad
ca
usa
use
measur
viral
load
serum
lung
tissu
polymeras
chain
reaction
pcr
amplif
perform
fast
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
accord
manufactur
guidelin
onestep
qrtpcr
perform
total
contain
templat
rna
rtpcr
buffer
forward
revers
primer
pmol
final
concentr
pmol
taqman
probe
pmol
final
concentr
pmol
rnase
inhibitor
ribolock
tm
thermo
fisher
scientif
inc
germani
rtpcr
enzym
mix
nucleasefre
water
cycl
condit
follow
revers
transcript
min
c
b
activ
step
c
c
cycl
c
c
sampl
threshold
cycl
c
cycl
fewer
consid
posit
standard
curv
gener
known
viru
titer
use
calcul
amount
prrsv
sampl
convert
c
valu
tcid
ml
equival
repeat
measur
analysi
varianc
anova
use
analyz
signific
differ
among
treatment
group
vitro
evalu
effect
dinap
prrsv
replic
cell
serum
viremia
serum
elisa
antiprrsv
igg
result
mannwhitney
u
test
nonparametr
test
use
analyz
signific
differ
among
group
adwg
lung
lesion
gross
microscop
viral
load
lung
tissu
p
indic
statist
signific
differ
graph
pad
prism
graphpad
softwar
inc
ca
usa
use
produc
graph
statist
analysi
perform
use
spss
advanc
statist
softwar
spss
inc
chicago
il
usa
acknowledg
author
happi
acknowledg
undergradu
student
laboratori
technician
colleg
veterinari
medicin
veterinari
diagnost
center
vdc
respect
chonbuk
nation
univers
assist
anim
experi
author
declar
conflict
interest
